BRAFV600E is by far the most common BRAF activating mutation in colorectal cancers [9], and associated with several distinct clinic-pathological parameters, such as proximal location, mucinous histology, microsatellite instability (MSI), female gender, higher age and grade, and poor prognosis after failure of standard chemotherapeutic regimens [10, 11]. This evidence concerns the gene BRAF and colorectal cancer.